Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
Open Access
- 22 July 2021
- Vol. 13 (8), 1421
- https://doi.org/10.3390/v13081421
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the currently approved SARS-CoV-2 vaccines use the prototype strain-derived spike (S) protein or its receptor-binding domain (RBD) as the vaccine antigen. The emergence of several novel SARS-CoV-2 variants has raised concerns about potential immune escape. In this study, we performed an immunogenicity comparison of prototype strain-derived RBD, S1, and S ectodomain trimer (S-trimer) antigens and evaluated their induction of neutralizing antibodies against three circulating SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.617.1. We found that, at the same antigen dose, the RBD and S-trimer vaccines were more potent than the S1 vaccine in eliciting long-lasting, high-titer broadly neutralizing antibodies in mice. The RBD immune sera remained highly effective against the B.1.1.7, B.1.351, and B.1.617.1 variants despite the corresponding neutralizing titers decreasing by 1.2-, 2.8-, and 3.5-fold relative to that against the wild-type strain. Significantly, the S-trimer immune sera exhibited comparable neutralization potency (less than twofold variation in neutralizing GMTs) towards the prototype strain and all three variants tested. These findings provide valuable information for further development of recombinant protein-based SARS-CoV-2 vaccines and support the continued use of currently approved SARS-CoV-2 vaccines in the regions/countries where variant viruses circulate.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2020YFC0845900)
- China Postdoctoral Science Foundation (2020T130118ZX)
This publication has 17 references indexed in Scilit:
- Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infectionsNature Communications, 2021
- Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EMScience Advances, 2021
- Viral targets for vaccines against COVID-19Nature Reviews Immunology, 2020
- Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancementCell Discovery, 2020
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARSCell, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)International Journal of Surgery, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019The New England Journal of Medicine, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020